Aggressive Treatment of High-Density Lipoprotein Cholesterol
Authors: Stephen J. Nicholls
Journal: Annals of Internal Medicine (2005)

Letters21 June 2005Aggressive Treatment of High-Density Lipoprotein CholesterolStephen J. Nicholls, MBBS, PhDStephen J. Nicholls, MBBS, PhDFrom the Cleveland Clinic Foundation, Cleveland, OH 44195.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-142-12_Part_1-200506210-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Whitney and colleagues (1) provide an interesting glimpse into the agents that elevate high-density lipoprotein (HDL) cholesterol levels in the prestatin era. The combination of a fibrate, niacin, and a bile-acid sequestrant increased plasma HDL levels by 37%. This was associated with a beneficial impact on atherosclerotic burden and a combination of clinical end points. Careful follow-up resulted in effective adherence to both dietary modification and consumption of pharmacologic agents that have traditionally been associated with high intolerability rates.The reported effect on plaque burden should be interpreted with caution. Atherosclerotic extent was measured by coronary angiography, ...References1. Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolasa MW, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med. 2005;142:95-104. [PMID: 15657157] LinkGoogle Scholar2. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized, controlled trial. JAMA. 2003;290:2292-300. [PMID: 14600188] CrossrefMedlineGoogle Scholar3. Pineda Torra I, Gervois P, Staels B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol. 1999;10:151-9. [PMID: 10327283] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Stephen J. Nicholls, MBBS, PhDAffiliations: From the Cleveland Clinic Foundation, Cleveland, OH 44195.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoA Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events Edwin J. Whitney , Richard A. Krasuski , Bradley E. Personius , Joel E. Michalek , Ara M. Maranian , Mark W. Kolasa , Erik Monick , B. Gregory Brown , and Antonio M. Gotto Jr. Aggressive Treatment of High-Density Lipoprotein Cholesterol Richard A. Krasuski and Edwin J. Whitney Aggressive Treatment of High-Density Lipoprotein Cholesterol Richard A. Krasuski and Edwin J. Whitney Metrics Cited byThe hypertension peril: Lessons from CETP inhibitors 21 June 2005Volume 142, Issue 12_Part_1Page: 1025KeywordsAngiographyBlood plasmaCholesterolInflammationNiacinStable coronary artery diseaseStatinsStenosisUltrasound imaging ePublished: 21 June 2005 Issue Published: 21 June 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...